Skip to content
Subscriber Only

Bristol Immune Drug Success in Cancer May Spur Industry Race

Updated on

The early success of an experimental drug from Bristol-Myers Squibb Co. that’s designed to unleash the body’s immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.

The drug shrank tumors in people with advanced lung, kidney and skin cancer in 18 percent to 28 percent of patients, depending on the illness, who had failed on other therapies, according to data from a 296-patient trial reported June 2 at the American Society of Clinical Oncology meeting in Chicago.